Get started
Author

Alejandro Ríos-Hoyo

Observed names: A. Rios Hoyo, A. Rios-Hoyo, A. Ríos-Hoyo, Alejandro Rios, Alejandro Rios Hoyo, Alejandro Rios-Hoyo
Institution: Hospital Del Mar
Observed institutions: Universitat Pompeu Fabra, Yale Cancer Center, Yale University, Universidad Anáhuac, Hospital Del Mar, Parc de Salut, Hospital del Mar Research Institute, Centro de Investigación Biomédica en Red de Cáncer
ORCID: 0000-0001-5344-9168
Observed ORCID: 0000-0001-5344-9168
OpenAlex ID: A5028683924
New Dietary Supplements for Obesity: What We Currently Know
2016 · Alejandro Ríos-Hoyo, Gabriela Gutiérrez-Salmeán · Current Obesity Reports · 127
Evaluation of large language models as a diagnostic aid for complex medical cases
2024 · Alejandro Ríos-Hoyo, Naing Lin Shan, et al. · Frontiers in Medicine · 68
Obesity, Metabolic Syndrome, and Dietary Therapeutical Approaches with a Special Focus on Nutraceuticals (Polyphenols): A Mini-Review
2014 · Alejandro Ríos-Hoyo, María J. Cortés, et al. · International Journal for Vitamin and Nutrition Research · 56
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
2024 · Alejandro Ríos-Hoyo, Xavier Monzonís, et al. · Frontiers in Pharmacology · 44
PDF
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
2023 · Alejandro Rios-Hoyo, Edurne Arriola · Frontiers in Immunology · 35
PDF
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
2022 · Alejandro Ríos-Hoyo, Laura Moliner, et al. · Cancers · 34
PDF
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
2024 · Alejandro Ríos-Hoyo, Erin Cobain, et al. · Journal of Clinical Oncology · 31
Clinical Implications of Breast Cancer Intrinsic Subtypes
2025 · Alejandro Rios-Hoyo, Naing-Lin Shan, et al. · Advances in experimental medicine and biology · 21
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
2020 · David Conde-Estévez, Inés Monge-Escartín, et al. · Journal of Chemotherapy · 20
Prognostic factors in oncological patients with solid tumours requiring intensive care unit admission
2023 · Raquel Bosch‑Compte, Laura Visa, et al. · Oncology Letters · 17
PDF
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
2022 · Alejo Rodriguez-Vida, Pablo Maroto, et al. · British Journal of Cancer · 15
Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
2024 · Alejandro Rios-Hoyo, Kaitlyn Xiong, et al. · Clinical Cancer Research · 12
PDF
Prehispanic Functional Foods and Nutraceuticals in the Treatment of Dyslipidemia Associated to Cardiovascular Disease: a Mini-Review
2017 · Alejandro Ríos-Hoyo, Alejandra Romo-Araiza, et al. · International Journal for Vitamin and Nutrition Research · 11
Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review
2025 · Ismail Ajjawi, Mariya Rozenblit, et al. · Cancers · 9
PDF
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
2025 · A. Rios-Hoyo, J. Dai, et al. · ESMO Open · 9
PDF
Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
2023 · S. David Nathanson, Lothar C. Dieterich, et al. · Clinical & Experimental Metastasis · 8
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
2025 · Ismail Ajjawi, Alejandro Rios, et al. · Breast Cancer Research and Treatment · 5
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
2024 · Vignesh Gunasekharan, Hao-Kuen Lin, et al. · Breast Cancer Research and Treatment · 5
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.
2024 · Alejandro Rios-Hoyo, Kaitlyn Xiong, et al. · Journal of Clinical Oncology · 5
Variability of apparent diffusion coefficients in metastatic small cell lung carcinoma: comparisons between-within normal tissue and liver metastases
2014 · Ernesto Roldán-Valadez, David Cortez-Conradis, et al. · Annals of Hepatology · 5
PDF
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance
2024 · Alexandra Lebedeva, Ekaterina Belova, et al. · Molecular Diagnosis & Therapy · 4
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
2025 · Ismail Ajjawi, Alejandro Rios, et al. · Cancers · 2
PDF
Transcriptomics-Driven Machine Learning Models Accurately Predict Chemotherapy Response in Muscle-invasive Bladder Cancer
2024 · Ariadna Acedo-Terrades, Alejo Rodriguez-Vida, et al. · medRxiv · 1
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer
2026 · Miguel A. Galindo-Campos, Max Hardy-Werbin, et al. · Frontiers in Immunology
Brief report: Artificial intelligence meets small cell lung cancer—integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC
2026 · Pedro Rocha, Joan Gibert, et al. · Frontiers in Artificial Intelligence
PDF
Works count: 44
Citation count: 544
H-index: 12
I10-index: 13
Year
Topic
Type